Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development servicesSyngene International, a global contract research, development, and manufacturing organization (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster. The investments included a dedicated, state-of-the-art
Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31st, 2024.Key Financial HighlightsQ3 FY25 HighlightsRevenue from operations at Rs. 52,691 mn, up 17% over last year. Research & Development (R&D) investments for the quarter stood
Company reports resilient performance in the nine months to date: revenue from operations up 17% to Rs 2,572 crores, PAT up 16% to Rs 330 crores (before exceptional items)Syngene International Limited today announced its third quarter financial results. Reported revenue from operations for the quarter
